Updates in the Treatment of Metastatic Colorectal Cancer

Molecular biomarker testing for all patients with metastatic colorectal cancer (CRC) has become increasingly important because identifying targetable alterations can lead to meaningful clinical benefits. At a minimum, should include RAS , BRAF mutational status, microsatellite instability HER2 expression, NTRK and RET mutations. For -amplified cancer, the NCCN Guidelines offer multiple treatment options, including trastuzumab in combination tucatinib or pertuzumab, trastuzumab-deruxtecan. Combination + recently received approval by FDA refractory wild-type, HER2-amplified CRC. The addition of bevacizumab trifluridine/tipiracil significantly prolonged median overall survival compared alone, regardless molecular subtypes. KRAS G12C–targeted therapies are on horizon, several agents ongoing studies. Furthermore, bilevel blockade is when addressing MAP kinase pathway alterations.